Background and Objectives: Respimat® Soft Mist™ Inhaler (SMI) is an innovative device that offers improved lung deposition and is an environmentally friendly alternative to conventional, chlorofluorocarbon-containing metered-dose inhalers (CFC-MDIs). The aqueous formulations of bronchodilator drugs administered from Respimat SMI contain low concentrations of ethylene diamine tetra-acetic acid (EDTA), a stabilising agent, and benzalkonium chloride (BAC), an antibacterial agent, both of which have been associated with bronchoconstriction when administered via nebulisers. The aim of this retrospective analysis was to compare the incidence of paradoxical bronchoconstriction with bronchodilator drugs administered via Respimat SMI or a CFC-MDI in patients with asthma or chronic obstructive pulmonary disease (COPD). Methods: Nine randomised, active- and/or placebo-controlled, double-blind, crossover studies, in which asthmatic and COPD patients (n = 444 and n = 216, respectively) received a β2-agonist and/or anticholinergic or placebo via Respimat SMI or CFC-MDI, were included in the analysis. The incidence of conditions indicative of paradoxical bronchoconstriction were collated and divided into four categories: (1) ‘bronchospasm’; (2) two or more of the following events: ‘other respiratory adverse events’, ‘rescue medication use’ or ‘asymptomatic drop in forced expiratory volume in one second’ (FEV1); (3) either ‘rescue medication use’ or ‘other respiratory adverse event’; (4) ‘asymptomatic drop in FEV1’. Results: The incidence of adverse events indicative of paradoxical bronchoconstriction was low in those patients using the Respimat SMI device, and similar to that seen in the CFC-MDI group. In addition, the incidence of adverse events indicative of paradoxical bronchoconstriction observed in the Respimat SMI group was similar for BAC + EDTA and BAC-only drug formulations. Conclusions: These studies demonstrate that, due to the extremely low absolute amounts of BAC and EDTA delivered to the lungs by the device, Respimat SMI is safe with regard to paradoxical bronchoconstriction in patients with asthma or COPD.

1.
Hochrainer D, Hoelz H: Comparison of cloud velocities delivered from Respimat® soft mist inhaler or MDIs. J Aerosol Med 2001;14(suppl 3):386.
2.
Zierenberg B, Eicher J, Dunne S, Freund B: Boehringer Ingelheim nebulizer BINEB: A new approach to inhalation therapy; in Dalby RN, Byron PR, Farr SJ (eds): Respiratory Drug Delivery V. Buffalo Grove, Interpharm Press, 1996, pp 187–193.
3.
Newman SP, Steed KP, Reader SJ, Hooper G, Zierenberg B: Efficient delivery to the lungs of flunisolide aerosol from a new portable hand-held multidose nebulizer. J Pharm Sci 1996:85:960–964.
4.
Newman SP, Steed KP, Towse L, Zierenberg B: The BINEB® (final prototype): A novel hand-held multidose nebuliser evaluated by gamma scintigraphy. Eur Respir J 1996;9(suppl 23):S441–S442.
5.
Steed KP, Towse LJ, Freund B, Newman SP: Lung and oropharyngeal depositions of fenoterol hydrobromide delivered from prototype III hand-held multidose Respimat® nebuliser. Eur J Pharm Sci 1997;5:55–61.
6.
Newman SP, Brown J, Steed KP, Reader SJ, Kladders H: Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines. Comparison of Respimat® with conventional metered-dose inhalers with and without spacer devices. Chest 1998;113:957–963.
7.
Pavia D, Moonen D: Preliminary data from phase II studies with Respimat®, a propellant-free soft mist inhaler. J Aerosol Med 1999;12(suppl 1):S33–S39.
8.
Smith SJ, Bernstein JA: Therapeutic use of lung aerosols; in Lenfant C (ed): Lung Biology in Health and Disease: Inhalation Aerosols. New York, Dekker, 1996, vol 94, pp 233–269.
9.
Pavia D: Efficacy and safety of inhalation therapy in chronic obstructive pulmonary disease and asthma. Respirology 1997;2(suppl 1):S5–S10.
10.
Crompton GK: Problems patients have using pressurized aerosol inhalers. Eur Respir Dis Suppl 1982;119:101–104.
11.
Larsen JS, Hahn M, Ekholm B, Wick KA: Evaluation of conventional press-and-breathe metered-dose inhaler technique in 501 patients. J Asthma 1994;31:193–199.
12.
Erickson S, Horton A, Kirking D: Assessing metered dose inhaler technique: Comparison of observation versus patient self-report. J Asthma 1998;35:575–583.
13.
Van Beerendonk I, Mesters I, Mudde A, Tan TD: Assessment of the inhalation technique in out-patients with asthma or chronic obstructive pulmonary disease using a metered dose inhaler or dry powder device. J Asthma 1998;35:273–279.
14.
Kamps A, Brand P, Roorda R: Determinants of correct inhalation technique in children attending a hospital-based asthma clinic. Acta Paediatr 2002;91:159–163.
15.
Hirst P, Pitcairn G, Richards J, Rohatagi S, Gillen M, Newman SP: Deposition and pharmacokinetics of an HFA formulation of triamcinolone acetonide delivered by pressurized metered dose inhaler. J Aerosol Med 2001;14:155–165.
16.
Berg E, Madsen J, Bisgaard H: In vitro performance of three combinations of spacers and pressurized metered dose inhalers for treatment in children. Eur Respir J 1998;12:472–476.
17.
Partridge MR: Metered-dose inhalers and CFCs: What respiratory physicians need to know. Respir Med 1994;88:645–647.
18.
Burnell P, Small T, Doig S, Johal B, Jenkins R, Gibson G: Ex-vivo product performance of Diskus and Turbuhaler inhalers using inhalation profiles from patients with severe chronic obstructive pulmonary disease. Respir Med 2001;95:324–330.
19.
Everard M, Devadason S, Souef P: Flow early in the inspiratory manoeuvre affects the aerosol particle size distribution from a Turbuhaler. Respir Med 1997;91:624–628.
20.
Nicklas RA: Paradoxical bronchospasm associated with the use of inhaled beta agonists. J Allergy Clin Immunol 1990;85:959–964.
21.
Miszkiel KA, Beasley R, Rafferty P, Holgate ST: The contribution of histamine release to bronchoconstriction provoked by inhaled benzalkonium chloride in asthma. Br J Clin Pharmacol 1988;25:157–163.
22.
Zhang YG, Wright WJ, Tam WK, Nguyen-Dang TH, Salone CM, Woolcock AJ: Effect of inhaled preservatives on asthmatic subjects. II. Benzalkonium chloride. Am Rev Respir Dis 1990;141:1405–1408.
23.
Beasley R, Fishwick D, Miles JF, Hendeles L: Preservatives in nebulizer solutions: Risks without benefit. Pharmacotherapy 1998;18:130–139.
24.
Maesen FPV, Van Noord JA, Smeets JJ, Greefhorst APM, Dewberry H, Cornelissen PJG: Dose-range finding study comparing a new soft mist inhaler with a conventional metered dose inhaler (MDI) to deliver fenoterol in patients with asthma (abstract). Eur Respir J 1997:10(suppl 25):128S.
25.
Goldberg J, Freund E, Jahnel B, Hinzmann R, on behalf of the Berodual Respimat® study team. Combination fenoterol/ipratropium bromide delivered via a new soft mist inhaler: Dose-range finding study in patients with asthma, in comparison with a conventional metered dose inhaler (MDI) (abstract). Am J Respir Crit Care Med 1998;157:A401.
26.
Data on file; Boehringer Ingelheim: Study U97–3212. 1997.
27.
Littner M, Taylor JR, Ghafouri M, Witek TJ, Sepulveda CA, Tacoma WA, Ridgefield CT: A dose-ranging study of ipratropium bromide solution delivered via a novel soft mist inhaler in patients with chronic obstructive pulmonary disease (COPD) (abstract). Eur Respir J 2000;16(suppl 31):55S.
28.
Data on file; Boehringer Ingelheim: Study U97–3214. 1997.
29.
Vincken W, Aumann J, Radermecker M, Slabbynck H, Stappaerts I, Demedts M, Moonen D: Comparison of pharmacodynamics, efficacy and safety of fenoterol inhaled from a novel pocket-sized inhaler and from a metered-dose inhaler (MDI) (abstract). Eur Respir J 1997:10(suppl 25):239S.
30.
Kunkel G, Magnussen H, Bergmann KC, Juergens UR, de Mey C, Freund E, Hinzmann R, Beckers B: Respimat® (a new soft mist inhaler) delivering fenoterol plus ipratropium bromide provides equivalent bronchodilation at half the cumulative dose compared with a conventional metered dose inhaler in asthmatic patients. Respiration 2000;67:306–314.
31.
Data on file; Boehringer Ingelheim: Study U97–0123. 1997.
32.
Iacono P, Velicitat P, Guemas E, Leclerc V, Thébault J-J: Improved delivery of ipratropium bromide using Respimat® (a new soft mist inhaler) compared with a conventional metered dose inhaler: Cumulative dose response study in patients with COPD. Respir Med 2000;94:490–495.
33.
Hodder RV, Pavia D, Dewberry H, Alexander KM, Iacono P, Ponitz HH, Beck E: Comparison of the safety relating to paradoxical bronchoconstriction of ipratropium bromide alone or combined with fenoterol hydrobromide inhaled from a new soft mist inhaler and from a conventional metered dose inhaler in asthma and COPD patients. Eur Respir J 2002;20:246S.
34.
Beasley CR, Rafferty P, Holgate ST: Bronchoconstrictor properties of preservatives in ipratropium bromide (Atrovent) nebuliser solution. BMJ 1987;9:1197–1198.
35.
Asmus MJ, Barros MD, Liang J, Chesrowan SE, Hendeles L: Pulmonary function response to EDTA, an additive in nebulised bronchodilators. J Allergy Clin Immunol 2001;107:68–72.
36.
Yarbrough J, Mansfield LE, Ting S: Metered dose inhaler-induced bronchospasm in asthmatic patients. Ann Allergy 1985;55:25–27.
37.
Kwong T, Flatt A, Crane J, Beasley R: The effect of benzalkonium chloride on the bronchodilator response to salbutamol nebuliser solution. NZ Med J 1990;103:457.
38.
Rafferty P, Beasley R, Holgate ST: Comparison and the efficacy of preservative free ipratropium bromide and Atrovent nebuliser solution. Thorax 1988;43:446–450.
39.
Henry RL, Hankin RG, Abramson R: Comparison of preservative-free and preservative-containing ipratropium bromide. Aust Paediatr J 1989;25:86–88.
40.
Orehek J Charpin D, Velardocchio JM, Grimaud C: Bronchomotor effect of bronchoconstriction-induced deep inspirations in asthmatics. Am Rev Respir Dis 1980;121:297–305.
41.
Orehek J, Nicoli MM, Delpierre S, Beaupre A: Influence of the previous deep inspiration on the spirometric measurement of provoked bronchoconstriction in asthma. Am Rev Respir Dis 1981;123:269–272.
42.
Charpin D, Beaupre A, Orehek J: Deep-inspiration induced bronchoconstriction: A mechanism for beclomethasone aerosol intolerance. Eur J Respir Dis 1983;64:494–497.
43.
Fryer A, Maclagan J: Ipratropium bromide potentiates bronchoconstriction induced by vagal nerve stimulation in the guinea-pig. Eur J Pharmacol 1987;139:187–191.
44.
Cocchetto DM, Sykes RS, Spector S: Paradoxical bronchoconstriction after use of inhalation aerosols: A review of the literature. J Asthma 1991;28:49–53.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.